Research Article
Theoretical Investigation of the Structural, Spectroscopic,
Electronic, and Pharmacological Properties of
4-Nerolidylcathecol, an Important Bioactive Molecule
RenyerA.Costa ,
1
EarleSilvaA.Junior,
2
JaquelinedeA.Bezerra,
2
JosianaMoreiraMar,
1
Emerson S. Lima ,
3
Maria Lucia B. Pinheiro,
1
Diego V. C. Mendonça,
1
Guilherme Braule P. Lopes,
1
Adjane Dalvana S. Branches,
1
and Kelson M. T. Oliveira
1
1
Department of Chemistry, Federal University of Amazonas (DQ-UFAM), 69077-000 Manaus, AM, Brazil
2
Federal Institute of Science and Technology of Amazonas (IFAM), 69020-120 Manaus, AM, Brazil
3
Faculty of Pharmaceutical Sciences, Federal University of Amazonas, 69077-000 Manaus, AM, Brazil
CorrespondenceshouldbeaddressedtoRenyerA.Costa;renyer.costa@gmail.com
Received 30 June 2018; Accepted 18 November 2018; Published 13 January 2019
AcademicEditor:FranckRabilloud
Copyright©2019RenyerA.Costaetal.isisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
4-Nerolidylcatechol(4NRC),asecondarymetabolitedescribedasapotentantioxidantthatpresentsanti-inflammatory,antimalarial,
analgesic,andcytotoxicproperties,hasbeenreceivingprominenceinthecatecholclass.Inthiswork,atheoreticalDFTstudyofthe
vibrational,structural,andquantumpropertiesof4-nerolidylcatechol(4NRC)usingtheB3LYP/6-311G(2d,p)levelispresented.e
theoretical molecular geometry data were compared with the X-ray data of a similar molecule in the associated literature and a
conformational study is presented, with the aim of providing a good comprehension of the 4NRC structural arrangement and
stability. Also, HOMO-LUMO energy gap and natural bond orbitals (NBOs) were performed and discussed. e calculated UV
spectrumshowedsimilaritytotheexperimentallyobtaineddata,withtransitionsassigned.ecomparativeIRstudiesrevealedthat
intermolecular hydrogen bonds that stabilize dimeric forms are plausible and also allowed the assignment of several characteristic
vibrations. Molecular docking calculations with DNA topoisomerase I-DNA complex (TOPO-I), glyceraldehyde 3-phospate de-
hydrogenase(GAPDH),and Plasmodium falciparum lactatedehydrogenase(PfLDH)showedbindingfreeenergiesof −6.3, −6.5,and
−7.6kcal/mol, respectively, which indicates that 4NRC is a good competitive inhibitor for these enzymes.
1.Introduction
Catechols are a group of small molecules with physiological
importance, acting as effective structural units in many ad-
renergic, Parkinson’s disease [1], attention-deficit hyperac-
tivity disorder (ADHD) [2], bronchodilator, antidepressants,
antihypertensive drugs, perfumes, and agrochemical ingre-
diants (for the production of pesticides) [3]. In organic
chemistry, catechol (1,2-dihydroxybenzene) and its de-
rivatives have widely attracted scientists since decades prin-
cipally for the design of mussel-inspired synthetic adhesives
andcoatings[4].Withrespecttotheirbiologicalimportance,
catechols can occur as metabolites [5, 6] or as endogenous
compounds,suchasneurotransmitterandtheirprecursorsas
adrenaline, noradrenaline, dopamine, and L-DOPA [1, 5, 6].
Catechols could act as antioxidants, preventing lipid perox-
idation, and as pro-oxidant-damaging macromolecules such
as DNA [7].
Animportantrepresentativeofthisclassofmoleculesis
4-nerolidylcatechol (4NRC) (Figure 1). Its potent antioxi-
dantactivityislargelyestablishedintheliterature[8–12],but
other pharmacological properties, such as antimicrobial
[13], analgesic, anti-inflammatory [14], cytotoxic [15, 16],
andantimalarialactivities[17]arerelatedto4NRC.Itisthe
major secondary metabolite of Piper genus plants, tradi-
tionally known for their use in the treatment of various
diseases [12, 15, 17–20]. However, the therapeutic appli-
cabilityof4NRCislimitedbyitsverypoorwatersolubility.
Many works in the literature have discussed the phar-
macological properties [10, 12, 16, 18–22] of 4NRC, but
Hindawi
Journal of Chemistry
Volume 2019, Article ID 9627404, 14 pages
https://doi.org/10.1155/2019/9627404